ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD
ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD
ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMDhttps://eyevensys.com/wp-content/themes/crocal/images/empty/thumbnail.jpg150150EyevensysEyevensyshttps://eyevensys.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
Eyevensys presents data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).